Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes

Intensive Care Medicine

Volumn 40, Issue 1, 2014, Pages 141-

  Schuetz, Philipp ^a   Mueller, Beat ^a  

^a Kantonsspital Aarau   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROCALCITONIN;

ADVERSE OUTCOME; ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DRUG SAFETY; HUMAN; INTENSIVE CARE UNIT; LETTER; META ANALYSIS; MORBIDITY; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RISK FACTOR; TREATMENT FAILURE; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; SEPSIS; SHOCK, SEPTIC;

EID: 84891033316     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-013-3139-x     Document Type: Letter

References (3)

1. Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Marquez-Vacaro JA (2013) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. doi: 10.1007/s00134-013-3077-7
2. Schuetz P, Briel M, Mueller B (2013) Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 309:717-718
3. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bhatnagar N, Bucher HC, Briel M (2012) Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 9:CD007498